Pricing pressures peg back Lilly’s growth products

Lilly was still able to post modest sales growth of 3% to $5.1bn, despite the ongoing impact of generic competition to its big-selling erectile dysfunction drug Cialis (tadalafil), but ... Lilly has other new medicines rolling out to help it manage the

Trulicity’s ascent lifts Lilly

These new medicines will be needed to offset continued decline in its older blockbuster medicines, Cialis and Forteo and Humulin, which all earned over $1bn in 2018, but will start to

Brand teams: why are some smarter than others?

They defeat powerful incumbents, like Cialis did with Viagra, or they overcome health-system conservatism, as Abbot is doing with its FreeStyle Libre device.

FDA approves Sanofi's follow-on version of Lilly’s Humalog

Humalog is just one of Lilly’s big brands facing competition, along with erectile dysfunction therapy Cialis (tadalafil) and antiplatelet drug Effient (prasugrel), and the company recently announced sweeping job cuts

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]